Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4730406 | 0.83 | MAPK1 (0.48) | RAB9ASMN1; SMN2MEN1KMT2ACA1 | |
| SCHEMBL942143 | 0.83 | — | — | |
| SCHEMBL29417993 | 0.83 | — | — | |
| SCHEMBL1735138 | 0.82 | PDGFRB (0.49) | NPC1MAPTRAB9ASMN1; SMN2PDGFRB | |
| Ammonia Solution, Strong SCHEMBL28188381 | 0.81 | MEN1 (0.44) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL9155808 | 0.81 | NQO1 (0.52) | PIK3CDCYP2A6NPC1MAPTRAB9A | |
| SCHEMBL11153370 | 0.80 | NPC1 (0.67) | CYP2A6NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL1662273 | 0.80 | PIK3CD (0.73) | PIK3CDCYP2A6NPC1RAB9AMEN1 | |
| SCHEMBL9160187 | 0.78 | RAB9A (0.53) | PIK3CDNPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL13933757 | 0.78 | RXFP1 (0.54) | NPC1MAPTRAB9ASMN1; SMN2CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024258591-A2 | NOVEL INHIBITORS OF HISTONE DEMETHYLASES AND COMPOSITIONS AND METHODS THEREOF | XIANG YIBIN (US) | 2024-12-19 | — | — | WO | disclosed |
| US-9199983-B2 | 3-aryl-6-aryl-[1,2,4]triazolo[4,3-α]pyridines as inhibitors of cell proliferation and the use thereof | CAI SUIXIONG (CN) | 2015-12-01 | — | — | US | disclosed |
| US-9199983-B2 | 3-aryl-6-aryl-[1,2,4]triazolo[4,3-α]pyridines as inhibitors of cell proliferation and the use thereof | CAI SUIXIONG (CN) | 2015-12-01 | — | — | US | disclosed |
| US-8846677-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130280245-A1 | 3-Aryl-6-aryl-[1,2,4]triazolo[4,3-alpha]pyridines as Inhibitors of Cell Proliferation and the Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2013-10-24 | — | — | US | disclosed |
| US-20130280245-A1 | 3-Aryl-6-aryl-[1,2,4]triazolo[4,3-alpha]pyridines as Inhibitors of Cell Proliferation and the Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2013-10-24 | — | — | US | disclosed |
| US-8501739-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120232078-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-09-13 | — | — | US | disclosed |
| WO-2012065546-A1 | 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF | IMPACT THERAPEUTICS, INC. (CN) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012065297-A1 | 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF | IMPACT THERAPEUTICS, INC. (CN) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012065297-A1 | 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF | IMPACT THERAPEUTICS, INC. (CN) | 2012-05-24 | — | — | WO | disclosed |
| EP-2386554-A1 | Compounds active at the histamine H3 receptor | High Point Pharmaceuticals, LLC (US) | 2011-11-16 | — | — | EP | disclosed |
| EP-2233470-A1 | Histamine H3 receptor antagonists | High Point Pharmaceuticals, LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090312309-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-12-17 | — | — | US | disclosed |
| EP-1902028-A2 | HISTAMINE H3 RECEPTOR ANTAGONISTS | Novo Nordisk A/S (DK) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007003604-A2 | HISTS1MINE H3 RECEPTOR ANTAGONISTS | NOVO NORDISK A/S (DK) | 2007-01-11 | — | — | WO | disclosed |
| EP-0017438-B1 | SUBSTITUTED 3-ALKYL-6-PHENYL-1,2,4-TRIAZOLO(4,3-A)PYRIDINES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AMERICAN CYANAMID COMPANY (US) | 1983-03-02 | — | — | EP | disclosed |
| US-4242515-A | Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines | AMERICAN CYANAMID COMPANY (US) | 1980-12-30 | — | — | US | disclosed |
| EP-0017438-A1 | Substituted 3-alkyl-6-phenyl-1,2,4-triazolo(4,3-a)pyridines, processes for their preparation and pharmaceutical compositions containing them | AMERICAN CYANAMID COMPANY (US) | 1980-10-15 | — | — | EP | disclosed |
| US-4209626-A | Substituted 6-phenyl-1,2,4-triazolo[4,3-a]pyridines | AMERICAN CYANAMID COMPANY (US) | 1980-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232078-A1 | Novel Medicaments | HRH3, HRH4, HRH1 | PIK3CD 3134/4885CYP2A6 4039/4885NPC1 2646/4885 |
| US-20090312309-A1 | Novel Medicaments | HRH3, HRH4, HRH1 | PIK3CD 3134/4885CYP2A6 4039/4885NPC1 2646/4885 |
| US-20130280245-A1 | 3-Aryl-6-aryl-[1,2,4]triazolo[4,3-alpha]pyridines as Inhibitors of Cell Proliferation and the Use Thereof | MKI67, CCNI, CCNA1 | PIK3CD 2383/4885CYP2A6 441/4885NPC1 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.